Fox Run Management’s Corcept Therapeutics CORT Stock Holding History

Fox Run Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$476K	Buy	+5,476	New	+$331K	0.08%	499
2023 Q4	–	Sell	-8,085	Closed	-$220K	–	763
2023 Q3	$220K	Buy	+8,085	New	+$234K	0.07%	535
2023 Q1	–	Sell	-29,530	Closed	-$600K	–	697
2022 Q4	$600K	Buy	+29,530	New	+$740K	0.24%	117
2018 Q4	–	Sell	-15,015	Closed	-$211K	–	542
2018 Q3	$211K	Buy	+15,015	New	+$210K	0.09%	464

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's CORT Position: Q2 2026 in Review

Fox Run Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 5,476 shares worth $476K. The stake represents 0.08% of the portfolio and ranks #499 among its holdings. This is a return to the name: Fox Run Management previously reported a position in CORT as recently as Q3 2023.

Fox Run Management first reported a position in CORT in Q3 2018 and has held it in 4 quarters since. The position peaked at $600K in Q4 2022. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Fox Run Management held 5,476 shares of Corcept Therapeutics worth $476K as of Q2 2026.
Corcept Therapeutics was a new Fox Run Management position in Q2 2026.
Corcept Therapeutics made up 0.08% of Fox Run Management's portfolio in Q2 2026, its #499 holding.
Fox Run Management first reported a position in Corcept Therapeutics in Q3 2018 and has held it in 4 quarters since.
Fox Run Management's Corcept Therapeutics position peaked at $600K in Q4 2022.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.